Literature DB >> 1846350

Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).

B A Teicher1, S A Holden, T S Herman, E A Sotomayor, V Khandekar, K W Rosbe, T W Brann, T T Korbut, E Frei.   

Abstract

In order to study the mechanisms responsible for resistance to CDDP, 5 human tumor cell lines were made resistant to CDDP by repeated in vitro exposures. After cloning it was found that the cell lines developed were between 3.3-fold and 17-fold more resistant to CDDP than the parental cell lines at the IC90. These lines were also resistant to carboplatin and tetraplatin; however, resistance to tetraplatin was lower than to the other platinum complexes. Sensitivity was also assessed to Adria, MTX, 5-FU, chlorambucil, 4-HC, 4-HIF, BCNU, Thiotepa, HN2, Mito C and L-PAM, and no consistent cross-resistance was observed. As compared with the parental lines, non-protein sulfhydryl content was elevated in 3 resistant lines, and protein sulfhydryl was elevated in all 5 lines, as was glutathione-S-transferase activity. Measurements of platinum in whole cells and nuclei after exposure of the cultures to 25 microM CDDP for either 1 or 6 hr showed that nuclear levels reflected those in whole cells and that, per mg protein, platinum levels were lower in resistant cells at both time points. Formation of DNA cross-links, determined by alkaline elution, was lower in resistant cell lines than in parental cell lines, but did not correlate with the absolute cell kill observed. These results indicate that cellular resistance to CDDP often involves decreases in drug accumulation and increases in protein sulfhydryl content. Possible strategies for overcoming these mechanisms are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846350     DOI: 10.1002/ijc.2910470214

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.

Authors:  Helen H W Chen; Wen-Chung Chen; Zhang-Dong Liang; Wen-Bin Tsai; Yan Long; Isamu Aiba; Siqing Fu; Russell Broaddus; Jinsong Liu; Lynn G Feun; Niramol Savaraj; Macus Tien Kuo
Journal:  Expert Opin Ther Targets       Date:  2015-05-25       Impact factor: 6.902

2.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.

Authors:  Brian G Blair; Christopher A Larson; Preston L Adams; Paolo B Abada; Catherine E Pesce; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2010-10-07       Impact factor: 4.436

4.  Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.

Authors:  B A Teicher; D Chatterjee; J T Liu; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Cyclocreatine in cancer chemotherapy.

Authors:  B A Teicher; K Menon; D Northey; J Liu; D W Kufe; R Kaddurah-Daouk
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.

Authors:  S A Holden; B A Teicher; M F Robinson; D Northey; A Rosowsky
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Authors:  W P Petros; S G Chaney; D C Smith; J Fangmeier; M Sakata; T D Brown; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Authors:  Brian G Blair; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Authors:  E Frei; S A Holden; R Gonin; D J Waxman; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Transient cisplatin-resistant murine fibrosarcoma cell characterized by increased metallothionein content.

Authors:  H Eichholtz-Wirth; R Born; G Reidel; B Hietel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.